Multicohort Models in Cost-Effectiveness Analysis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Medical decision making

• Publication date

  2013-04-01

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.1177/0272989X12453503PMID 22927697PMCID PMC3606654
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model

  2012cited by this paper
• Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis

  2012influential reference
• Practical implications of differential discounting in cost-effectiveness analyses with varying numbers of cohorts.

  2011cited by this paper
• Appropriate Cohorts for Cost-Effectiveness Analysis: To Mix or Not to Mix?

  2010cited by this paper
• A Decision-Analytic Evaluation of the Cost-Effectiveness of Family History–Based Colorectal Cancer Screening Programs

  2010cited by this paper
• Stool DNA Testing to Screen for Colorectal Cancer in the Medicare Population

  2010cited by this paper
• Whose Costs and Benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts

  2010influential reference
• PCASE3 HTA PROCEDURES IN DRUG REIMBURSEMENT PROCESS IN POLAND. EVOLUTION OF RECOGNITION THE ROLE OF AGENCY OF HEALTH TECHNOLOGY ASSESSMENT (AHTAPOL) BY POLICY MAKERS

  2009cited by this paper
• Cost-Effectiveness Analysis of Mammography and Clinical Breast Examination Strategies: A Comparison with Current Guidelines

  2009cited by this paper
• Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.

  2009cited by this paper
• Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination.

  2008cited by this paper
• Guidelines for Pharmacoeconomic Evaluations in Belgium

  2008cited by this paper
• The cost‐effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?

  2008cited by this paper
• Cost-effectiveness of digital mammography breast cancer screening.

  2008cited by this paper
• A Critique and Impact Analysis of Decision Modeling Assumptions

  2007cited by this paper
• Modeling the impact of adjuvant therapy and screening mammography on U.S. breast cancer mortality between 1975 and 2000: introduction to the problem.

  2006cited by this paper
• Retrospective cost-effectiveness analysis of screening mammography.

  2006cited by this paper
• Impact of Generic Drug Entry on Cost-Effectiveness Analysis

  2005cited by this paper
• The Cost-Effectiveness of Screening Programs Using Single and Multiple Birth Cohort Simulations: A Comparison Using a Model of Cervical Cancer

  2004influential reference
• Cost-effectiveness analysis of two strategies for mass screening for colorectal cancer in France.

  2004cited by this paper
• The evaluation of disease prevention and treatment using simulation models

  2003cited by this paper
• Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity

  2003cited by this paper
• Cost-effectiveness of cervical cancer screening: comparison of screening policies.

  2002cited by this paper
• Costs and Effectiveness of Alternative Strategies for Cervical Cancer Screening in Military Beneficiaries

  2002cited by this paper
• Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective.

  1999cited by this paper
• Prevalence-based economic evaluation.

  1998cited by this paper
• The MISCAN simulation program for the evaluation of screening for disease.

  1985cited by this paper
• Cost-effectiveness of cervical cancer screening.

  1983cited by this paper

• Advances in Addressing Patient Heterogeneity in Economic Evaluation: A Review of the Methods Literature

  2024cites this paper
• Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis

  2024cites this paper
• Impact of 'EVEN FASTER' concept to accelerate cervical cancer elimination in Norway: A model-based analysis

  2023cites this paper
• The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data.

  2022cites this paper
• Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk Stratification

  2022cites this paper
• Risk Stratification in Cost-Effectiveness Analyses of Cancer Screening: Intervention Eligibility, Strategy Choice, and Optimality

  2021cites this paper
• Interpreting cost-effectiveness ratios in a cost-effectiveness analysis of risk-tailored prostate screening: A critique of Callender et al.

  2020cites this paper
• The Health Benefits, Resource Use and Cost-Effectiveness of Current and Future Cervical Cancer Screening Policies in Norway

  2018cites this paper
• Cost-Effectiveness Methods and Newborn Screening Assessment.

  2017cites this paper
• Impacto epidemiológico y económico del programa de detección precoz del cáncer de mama en el País Vasco: Desarrollo de un modelo de Simulación

  2016cites this paper
• Economic evaluation of the breast cancer screening programme in the Basque Country: retrospective cost-effectiveness and budget impact analysis

  2016cites this paper
• Cancer Care Coordinators to Improve Tamoxifen Persistence in Breast Cancer: How Heterogeneity in Baseline Prognosis Impacts on Cost-Effectiveness.

  2016cites this paper
• The effectiveness of FOBT vs. FIT: A meta-analysis on colorectal cancer screening test

  2016cites this paper
• Cancer mortality reductions were greatest among countries where cancer care spending rose the most, 1995-2007.

  2015cites this paper
• Simulazioa osasun alorreko politika publikoen ebaluaziorako baliabidea

  2015cites this paper
• A real options game approach to health technology assessment

  2015influential citation
• Characterizing Heterogeneity Bias in Cohort-Based Models

  2015cites this paper
• Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice

  2015cites this paper
• Beware of Kinked Frontiers: A Systematic Review of the Choice of Comparator Strategies in Cost-Effectiveness Analyses of Human Papillomavirus Testing in Cervical Screening.

  2015cites this paper
• Decision-Analytic Models: Current Methodological Challenges

  2014cites this paper
• Methods Development for Health Technology Assessment

  2013cites this paper